Abstract：Objective To investigate the effect of microRNA (miRNA)-622 on the proliferation and apoptosis of non-small cell lung cancer A549 cells.Methods A549 cells were cultured and divided into miRNA-622 group and miRNA-622 negative control group (NC group) transfected with miRNA-622 mimics and miRNA-622 negative controls, respectively. MiRNA-622 expression was detected using quantitative real-time polymerase chain reaction, cell proliferation was analyzed through methyl thiazolyl tetrazolium assay, and cell apoptosis rate was examined through flow cytometry.Results The miRNA-622 and NC groups had relative miRNA-622 expression levels of 0.993±0.058 and 0.631±0.053, respectively; OD values of 0.631±0.049 and 0.922±0.058, respectively; and apoptosis rates of 12.230%±0.176% and 7.400%±0.208%, respectively. The miRNA-622 group had higher relative miRNA-622 expression and apoptotic rate but lower OD value than the NC group, and the differences were statistically significant (t=23.650, 17.710, 3.822, all P values<0.01).Conclusions miRNA-622 can inhibit the proliferation and promote the apoptosis of A549 cells.
周海荣, 毕明宏. 微小RNA-622对非小细胞肺癌A549细胞增殖、凋亡的影响[J]. 中华解剖与临床杂志, 2020, 25(4): 421-424.
Zhou Hairong, Bi Minghong. Effects of microRNA-622 on the proliferation and apoptosis of non-small cell lung cancer A549 cells. Chinese Journal of Anatomy and Clinics, 2020, 25(4): 421-424.
Wang J, Li H. CircRNA circ_0067934 silencing inhibits the proliferation, migration and invasion of NSCLC cells and correlates with unfavorable prognosis in NSCLC[J]. Eur Rev Med Pharmacol Sci, 2018, 22(10): 3053-3060. DOI:10.26355/eurrev_201805_15063.
[2]
Skjefstad K, Johannessen C, Grindstad T, et al. A gender specific improved survival related to stromal miR-143 and miR-145 expression in non-small cell lung cancer[J]. Sci Rep, 2018, 8(1): 8549. DOI:10.1038/s41598-018-26864-w.
[3]
Yu D, Qin Y, Jun-Qiang L, et al. CNPY2 enhances resistance to apoptosis induced by cisplatin via activation of NF-κB pathway in human non-small cell lung cancer[J]. Biomed Pharmacother, 2018, 103: 1658-1663. DOI:10.1016/j.biopha.2018.04.123.
[4]
Sun B, Liu HF, Ding Y, et al. Evaluating the diagnostic and prognostic value of serum miR-770 in non-small cell lung cancer[J]. Eur Rev Med Pharmacol Sci, 2018, 22(10): 3061-3066. DOI:10.26355/eurrev_201805_15064.
[5]
Choi YE, Meghani K, Brault ME, et al. Platinum and PARP inhibitor resistance due to overexpression of microRNA-622 in BRCA1-mutant ovarian cancer[J]. Cell Rep, 2016, 14(3): 429-439. DOI:10.1016/j.celrep.2015.12.046.
[6]
Fang Y, Sun B, Li Z, et al. MiR-622 inhibited colorectal cancer occurrence and metastasis by suppressing K-Ras[J]. Mol Carcinog, 2016, 55(9): 1369-1377. DOI:10.1002/mc.22380.
[7]
Wang Y, Sun J, Wei X, et al. Decrease of miR-622 expression suppresses migration and invasion by targeting regulation of DYRK2 in colorectal cancer cells[J]. Onco Targets Ther, 2017, 10: 1091-1100. DOI:10.2147/OTT.S125724.
[8]
Li T, Sun X, Xu K. The suppressing role of miR-622 in renal cell carcinoma progression by down-regulation of CCL18/MAPK signal pathway[J]. Cell Biosci, 2018, 8: 17. DOI:10.1186/s13578-018-0212-8.
[9]
Wang R, Ma Q, Ji L, et al. miR-622 suppresses tumor formation by directly targeting VEGFA in papillary thyroid carcinoma[J]. Onco Targets Ther, 2018, 11: 1501-1509. DOI:10.2147/OTT.S156810.
[10]
Geng Y, Deng L, Su D, et al. Identification of crucial microRNAs and genes in hypoxia-induced human lung adenocarcinoma cells[J]. Onco Targets Ther, 2016, 9: 4605-4616. DOI:10.2147/OTT.S103430.
[11]
Song C, Lu P, Shi W, et al. MiR-622 functions as a tumor suppressor and directly targets E2F1 in human esophageal squamous cell carcinoma[J]. Biomed Pharmacother, 2016, 83: 843-849. DOI:10.1016/j.biopha.2016.07.036.
2020, Vol. 25 
